Application of Molecular Adsorbents Recirculating System to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome
Article first published online: 1 SEP 2003
Volume 23, Issue Supplement s3, pages 16–20, June 2003
How to Cite
Guo, L.-M., Liu, J.-Y., Xu, D.-Z., Li, B.-S., Han, H., Wang, L.-H., Zhang, W.-Y., Lu, L.-H., Guo, X., Sun, F.-X., Zhang, H.-Y., Liu, X.-D., Zhang, J.-P., Yao, Y., He, Z.-P. and Wang, M.-M. (2003), Application of Molecular Adsorbents Recirculating System to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome. Liver International, 23: 16–20. doi: 10.1034/j.1478-3231.23.s.3.7.x
- Issue published online: 1 SEP 2003
- Article first published online: 1 SEP 2003
- liver failure;
- artificial liver support;
Background: Molecular Adsorbents Recirculating System (MARS) is a new promising artificial liver support therapy, the aim of this study was to assess the effectiveness of MARS to remove nitrous oxide (NO) and cytokines in severe liver failure patients with multiple organ dysfunction syndrome (MODS).
Methods: Sixty single MARS treatments were performed with length of 6–24 h on 24 severe liver failure patients (18 males/6 females) with MODS.
Results: The MARS therapy was associated with a significant removal of NO and certain cytokines such as TNF-α, IL-6, IL-8, and INF-γ, together with marked reduction of other non-water-soluble albumin bound toxins and water-soluble toxins, these were associated with a improvement of the patients' clinical conditions including hepatic encephalopathy, deranged hemodynamic situation and as well as renal and respiratory function, thus resulted into marked decrease of Sequential Organ Failure Assessment (SOFA) score and improved outcome: nine patients were able to be discharged from the hospital or bridged to successful liver transplantation, the overall survival of 24 patients was 37.5%.
Conclusion: We can confirm the positive therapeutic impact and safety to use MARS on liver failure patients with MODS associated with elevated levels of NO and cytokines.